Dr. Ridong Chen This is Me

Education

 Web References

1. 1. APT Therapeutics™

   www.apttherapeutics.com/corp_d - [Cached]

   Published on: 6/29/2004   Last Visited: 6/29/2004

   Ridong Chen, Ph.D Chief Scientific Officer , APT Therapeutics

2. 2. CID Equity Partners:

   www.cidequity.com/news/index.c - [Cached]

   Published on: 6/3/2002   Last Visited: 11/27/2002

   "After the successful completion of the human genome project, protein-based technologies are key to translating genomic information into life saving therapeutics," said Ridong Chen, Ph.D., President and Chief Scientific Officer of APT Therapeutics. "We believe that our proprietary protein-enabled technologies and depth of cross-functional technical expertise, coupled with the strong financial commitment from the two leading VC firms in Midwest, will significantly accelerate the current drug discovery and improvement process and will create great value for our investors."
   
   APT Therapeutics is focusing its strengths in the area of protein engineering and protein informatics by developing novel therapeutic proteins as well as improving the efficacy of therapeutic proteins that failed to meet clinical expectations. In addition, APT Therapeutics is validating a revolutionary approach to computational drug design that will greatly enhance the speed and precision of improving small molecule pharmaceuticals. Together, these technology platforms put APT Therapeutics in the unique position of generating proprietary breakthrough drug candidates while also expanding the capabilities of established pharmaceutical companies through strategic partnerships.
   
   ...
   The Board of Directors includes Dr. Ridong Chen, APT Therapeutics; Peter Kleinhenz, CID Equity Partners; Dr. Brian Clevinger, Prolog Ventures; and Dr. Ganesh Kishore, Auxyn Bioscience Ventures.